Self-Host
Tools / Inside Trading Tracker
Inside Trading Tracker
Track insider trading activity at publicly traded companies to understand how executives are trading their shares.
AbbVie Inc. (ABBV) Insider Trading Activity
Healthcare • Drug Manufacturers - General • 50,000 employees
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Total Value
-$74,320,980.05
Total Shares
103,304
Average Trade Value
-$965,207.53
Most Active Insider
Gonzalez Richard A
Total Activity: $35,272,329
Largest Single Transaction
$18,964,471
by Gonzalez Richard A on Feb 28, 2025
30-Day Activity
75 Transactions
Volume: 103,304 shares
Value: $74,179,248
|
Name
|
Position
|
Date
|
Shares
|
Value
|
Holdings
|
Type
|
|---|---|---|---|---|---|---|
|
Evp, Gc and Secretary
|
Mar 3, 2025 | 2,918 | $421,768 | 7,537 (+38.7%) | Exercise/Conversion | |
|
Evp, Gc and Secretary
|
Mar 3, 2025 | 18,008 | $3,781,680 | 4,619 (-389.9%) | Sale | |
|
Evp, Gc and Secretary
|
Mar 3, 2025 | 7,775 | $1,362,802 | 22,627 (+34.4%) | Exercise/Conversion | |
|
Evp, Gc and Secretary
|
Mar 3, 2025 | 7,315 | $1,094,470 | 14,852 (+49.3%) | Exercise/Conversion | |
| Mar 3, 2025 | 6,168 | $1,298,549 | 388,929 (-1.6%) | Sale | ||
|
Evp, Chief Hr Officer
|
Mar 3, 2025 | 600 | $126,792 | 6,130 (-9.8%) | Sale | |
|
Evp, Chief Hr Officer
|
Mar 3, 2025 | 14,973 | $3,154,212 | 6,730 (-222.5%) | Sale | |
|
Evp, Chief Hr Officer
|
Mar 3, 2025 | 5,677 | $1,191,035 | 21,703 (-26.2%) | Sale | |
|
Evp, Gc and Secretary
|
Feb 28, 2025 | 363 | $75,210 | 4,619 (-7.9%) | Sale | |
| Feb 28, 2025 | 92,460 | $18,964,471 | 395,097 (-23.4%) | Sale | ||
|
Evp, Chief Bus/strat Officer
|
Feb 28, 2025 | 11,230 | $2,302,375 | 70,018 (-16.0%) | Payment of Exercise Price | |
|
Evp, Gc and Secretary
|
Feb 28, 2025 | 6,811 | $1,407,289 | 4,982 (-136.7%) | Sale | |
|
Evp, Rd and Cso
|
Feb 28, 2025 | 4,678 | $959,084 | 42,276 (-11.1%) | Payment of Exercise Price | |
| Feb 28, 2025 | 73,209 | $15,009,309 | 487,557 (-15.0%) | Payment of Exercise Price | ||
|
Evp, Chief Financial Officer
|
Feb 28, 2025 | 10,973 | $2,249,684 | 29,221 (-37.6%) | Payment of Exercise Price | |
|
Chief Executive Officer
|
Feb 28, 2025 | 27,186 | $5,573,674 | 132,821 (-20.5%) | Payment of Exercise Price | |
|
Evp, Chief Commercial Officer
|
Feb 28, 2025 | 20,226 | $4,146,735 | 86,366 (-23.4%) | Payment of Exercise Price | |
|
Evp, Chief Hr Officer
|
Feb 28, 2025 | 16,904 | $3,465,658 | 27,380 (-61.7%) | Payment of Exercise Price | |
|
Evp, Chief Operations Officer
|
Feb 28, 2025 | 17,056 | $3,496,821 | 177,292 (-9.6%) | Payment of Exercise Price | |
|
Svp, Controller
|
Feb 28, 2025 | 3,699 | $758,369 | 7,797 (-47.4%) | Payment of Exercise Price | |
|
Evp, Gc and Secretary
|
Feb 28, 2025 | 2,718 | $558,223 | 11,793 (-23.0%) | Sale | |
|
Evp, Gc and Secretary
|
Feb 28, 2025 | 7,870 | $1,613,507 | 14,511 (-54.2%) | Payment of Exercise Price | |
|
Svp, Controller
|
Feb 26, 2025 | 2,684 | $545,926 | 12,646 (-21.2%) | Sale | |
|
Svp, Controller
|
Feb 26, 2025 | 16,260 | $3,307,447 | 11,496 (-141.4%) | Sale | |
|
Evp, Chief Hr Officer
|
Feb 26, 2025 | 4,829 | $983,329 | 44,284 (-10.9%) | Sale | |
|
Svp, Controller
|
Feb 26, 2025 | 9,738 | $910,503 | 22,384 (+43.5%) | Exercise/Conversion | |
|
Evp, Chief Hr Officer
|
Feb 26, 2025 | 1,526 | $310,755 | 44,284 (-3.4%) | Sale | |
|
Svp, Controller
|
Feb 26, 2025 | 6,522 | $690,810 | 28,906 (+22.6%) | Exercise/Conversion | |
|
Evp, Chief Hr Officer
|
Feb 26, 2025 | 13,073 | $2,652,773 | 49,113 (-26.6%) | Sale | |
|
Evp, Chief Hr Officer
|
Feb 26, 2025 | 22,210 | $2,539,936 | 66,494 (+33.4%) | Exercise/Conversion | |
|
Evp, Chief Hr Officer
|
Feb 26, 2025 | 1,400 | $282,884 | 50,591 (-2.8%) | Sale | |
|
Evp, Chief Hr Officer
|
Feb 26, 2025 | 4,781 | $970,208 | 45,810 (-10.4%) | Sale | |
|
Evp, Chief Hr Officer
|
Feb 26, 2025 | 4,308 | $870,087 | 62,186 (-6.9%) | Sale | |
|
Evp, Gc and Secretary
|
Feb 20, 2025 | 1,784 | $352,162 | 26,375 (-6.8%) | Sale | |
|
Evp, Gc and Secretary
|
Feb 20, 2025 | 3,994 | $791,291 | 22,381 (-17.8%) | Sale | |
|
Evp, Chief Hr Officer
|
Feb 13, 2025 | 6,998 | $0 | 51,991 (+13.5%) | Grant | |
|
Evp, Chief Financial Officer
|
Feb 13, 2025 | 8,912 | $0 | 32,586 (+27.3%) | Grant | |
|
Evp, Chief Financial Officer
|
Feb 13, 2025 | 7,608 | $0 | 40,194 (+18.9%) | Grant | |
|
Evp, Chief Financial Officer
|
Feb 13, 2025 | 5,845 | $0 | 21,276 (+27.5%) | Grant | |
|
Evp, Chief Financial Officer
|
Feb 13, 2025 | 2,398 | $0 | 23,674 (+10.1%) | Grant | |
|
Evp, Chief Bus/strat Officer
|
Feb 13, 2025 | 5,174 | $0 | 81,248 (+6.4%) | Grant | |
|
Evp, Chief Operations Officer
|
Feb 13, 2025 | 6,060 | $0 | 225,772 (+2.7%) | Grant | |
|
Evp, Chief Operations Officer
|
Feb 13, 2025 | 17,986 | $0 | 212,334 (+8.5%) | Grant | |
|
Chief Executive Officer
|
Feb 13, 2025 | 24,732 | $0 | 123,377 (+20.0%) | Grant | |
|
Evp, Chief Operations Officer
|
Feb 13, 2025 | 7,378 | $0 | 219,712 (+3.4%) | Grant | |
|
Evp, Chief Operations Officer
|
Feb 13, 2025 | 7,074 | $0 | 232,846 (+3.0%) | Grant | |
|
Chief Executive Officer
|
Feb 13, 2025 | 10,146 | $0 | 133,523 (+7.6%) | Grant | |
|
Chief Executive Officer
|
Feb 13, 2025 | 14,454 | $0 | 160,007 (+9.0%) | Grant | |
|
Chief Executive Officer
|
Feb 13, 2025 | 12,030 | $0 | 145,553 (+8.3%) | Grant | |
|
Evp, Rd and Cso
|
Feb 13, 2025 | 3,595 | $0 | 39,994 (+9.0%) | Grant | |
|
Evp, Rd and Cso
|
Feb 13, 2025 | 2,138 | $0 | 43,606 (+4.9%) | Grant | |
|
Evp, Rd and Cso
|
Feb 13, 2025 | 1,474 | $0 | 41,468 (+3.6%) | Grant | |
|
Evp, Rd and Cso
|
Feb 13, 2025 | 3,348 | $0 | 46,954 (+7.1%) | Grant | |
|
Svp, Controller
|
Feb 13, 2025 | 3,595 | $0 | 10,578 (+34.0%) | Grant | |
|
Svp, Controller
|
Feb 13, 2025 | 1,474 | $0 | 12,052 (+12.2%) | Grant | |
|
Svp, Controller
|
Feb 13, 2025 | 1,604 | $0 | 13,656 (+11.7%) | Grant | |
|
Svp, Controller
|
Feb 13, 2025 | 1,674 | $0 | 15,330 (+10.9%) | Grant | |
| Feb 13, 2025 | 80,945 | $0 | 469,874 (+17.2%) | Grant | ||
| Feb 13, 2025 | 33,208 | $0 | 503,082 (+6.6%) | Grant | ||
| Feb 13, 2025 | 27,386 | $0 | 560,766 (+4.9%) | Grant | ||
| Feb 13, 2025 | 30,298 | $0 | 533,380 (+5.7%) | Grant | ||
|
Evp, Gc and Secretary
|
Feb 13, 2025 | 1,844 | $0 | 16,737 (+11.0%) | Grant | |
|
Evp, Gc and Secretary
|
Feb 13, 2025 | 5,792 | $0 | 22,529 (+25.7%) | Grant | |
|
Evp, Gc and Secretary
|
Feb 13, 2025 | 4,496 | $0 | 14,893 (+30.2%) | Grant | |
|
Evp, Gc and Secretary
|
Feb 13, 2025 | 5,630 | $0 | 28,159 (+20.0%) | Grant | |
|
Evp, Chief Commercial Officer
|
Feb 13, 2025 | 7,840 | $0 | 87,892 (+8.9%) | Grant | |
|
Evp, Chief Commercial Officer
|
Feb 13, 2025 | 9,268 | $0 | 97,160 (+9.5%) | Grant | |
|
Evp, Chief Commercial Officer
|
Feb 13, 2025 | 9,432 | $0 | 106,592 (+8.8%) | Grant | |
|
Evp, Chief Commercial Officer
|
Feb 13, 2025 | 19,111 | $0 | 80,052 (+23.9%) | Grant | |
|
Evp, Chief Bus/strat Officer
|
Feb 13, 2025 | 11,017 | $0 | 66,920 (+16.5%) | Grant | |
|
Evp, Chief Bus/strat Officer
|
Feb 13, 2025 | 4,634 | $0 | 76,074 (+6.1%) | Grant | |
|
Evp, Chief Bus/strat Officer
|
Feb 13, 2025 | 4,520 | $0 | 71,440 (+6.3%) | Grant | |
|
Evp, Chief Hr Officer
|
Feb 13, 2025 | 17,986 | $0 | 31,823 (+56.5%) | Grant | |
|
Evp, Chief Hr Officer
|
Feb 13, 2025 | 7,378 | $0 | 39,201 (+18.8%) | Grant | |
|
Evp, Chief Hr Officer
|
Feb 13, 2025 | 5,792 | $0 | 44,993 (+12.9%) | Grant | |
|
Svp, Controller
|
Dec 16, 2024 | 1,800 | $310,032 | 6,983 (-25.8%) | Sale | |
|
Svp, Controller
|
Dec 16, 2024 | 1,800 | $168,300 | 8,783 (+20.5%) | Exercise/Conversion |